$14.90 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About uniQure

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Stock Analysis

last close $14.9
1-mo return -1.7%
3-mo return -11.7%
avg daily vol. 524.04T
52-week high 38.8
52-week low 12.52
market cap. $640M
forward pe -
annual div. -
roe 79.1%
ltg forecast -
dividend yield -
annual rev. $445M
inst own. 91.5%

Subscribe now for daily local and international financial news